Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $23.8 million.

  • Tarsus Pharmaceuticals' Change in Accured Expenses rose 30630.54% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.5 million, marking a year-over-year increase of 5738.31%. This contributed to the annual value of $40.3 million for FY2024, which is 20466.01% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Change in Accured Expenses stood at $23.8 million, which was up 30630.54% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Change in Accured Expenses registered a high of $23.8 million during Q3 2025, and its lowest value of -$2.1 million during Q2 2022.
  • For the 5-year period, Tarsus Pharmaceuticals' Change in Accured Expenses averaged around $5.1 million, with its median value being $2.3 million (2025).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 151757.19% in 2021, then plummeted by 37709.75% in 2022.
  • Tarsus Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $357000.0 in 2021, then soared by 299.72% to $1.4 million in 2022, then skyrocketed by 465.03% to $8.1 million in 2023, then skyrocketed by 86.62% to $15.0 million in 2024, then soared by 58.45% to $23.8 million in 2025.
  • Its last three reported values are $23.8 million in Q3 2025, $2.3 million for Q2 2025, and $11.3 million during Q1 2025.